PERBANDINGAN EFEKTIVITAS REGIMEN ANTIBIOTIK LEVOFLOXACIN-BASED DAN CLARITHROMYCIN-BASED PADA ERADIKASI HELICOBACTER PYLORI
DOI:
https://doi.org/10.31004/jkt.v7i1.55069Keywords:
adverse effects, antibiotic regimens, clarithromycin-based therapy, helicobacter pylori, levofloxacin-based therapyAbstract
Infeksi Helicobacter pylori merupakan penyebab utama ulkus peptikum dan masih menjadi tantangan klinis global akibat meningkatnya resistensi antibiotik, khususnya terhadap clarithromycin yang telah lama digunakan sebagai terapi lini pertama. Peningkatan resistensi ini menyebabkan penurunan tingkat keberhasilan eradikasi sehingga diperlukan evaluasi terhadap regimen alternatif seperti terapi berbasis levofloxacin. Penelitian ini bertujuan membandingkan efektivitas dan keamanan regimen levofloxacin-based dan clarithromycin-based dalam eradikasi H. pylori. Studi ini merupakan penelitian sekunder dengan desain narrative literature review komparatif terhadap artikel yang dipublikasikan pada periode 2016–2025. Penelusuran literatur dilakukan melalui database Google Scholar, PubMed, ScienceDirect, dan NCBI, kemudian dipilih studi yang memenuhi kriteria inklusi berdasarkan relevansi, desain penelitian, serta kelengkapan data tingkat eradikasi dan efek samping. Data dianalisis secara naratif dengan membandingkan hasil eradikasi berdasarkan analisis intention-to-treat (ITT) dan per-protocol (PP) serta mengevaluasi profil tolerabilitas masing-masing regimen. Hasil sintesis menunjukkan bahwa sebagian besar studi melaporkan tingkat eradikasi lebih tinggi pada regimen berbasis levofloxacin dengan kisaran 74–91,8%, dibandingkan clarithromycin yang berkisar 51,7–83%. Keunggulan ini lebih konsisten pada terapi berdurasi 10–14 hari dan di wilayah dengan resistensi clarithromycin tinggi, meskipun beberapa penelitian menunjukkan hasil yang setara. Secara keseluruhan, regimen berbasis levofloxacin menunjukkan kecenderungan efektivitas dan keamanan yang lebih baik dalam eradikasi H. pylori pada berbagai populasi penelitian.References
Ahmed, I., Bano, K., Shabbir, K., Razzaq, K., Khan, R. S. A., & Iqbal, Q. (2025). Comparative effectiveness of levofloxacin-based triple regimen and standard clarithromycin-based triple regimen in eradication of Helicobacter pylori: Insights from a peripheral hospital-based study. Life and Science, 6(2), 236–241. https://doi.org/http://doi.org/10.37185/LnS.1.1.341
Alsaadi, N. T. A., Alsaadi, M. T. A., & Ali, Z. T. (2020). Comparison between levofloxacin-based therapy and clarithromycin-based therapy through 14 days period for H. pylori eradication. Systematic Reviews in Pharmacy, 11(4), 593–598. https://doi.org/10.31838/srp.2020.4.88
Arj, A., Mollaei, M., Razavizadeh, M., & Moraveji, A. (2020). The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication. Journal of Research in Pharmacy Practice, 9, 101–105. https://doi.org/10.4103/jrpp.JRPP
Azab, E. T., Thabit, A. K., Mckee, S., & Al-Qiraiqiri, A. (2022). Levofloxacin versus clarithromycin for Helicobacter pylori eradication : are 14 day regimens better than 10 day regimens? Gut Pathogens, 14(24), 1–7. https://doi.org/10.1186/s13099-022-00502-3
DiPiro, J. T., Yee, G. C., Haines, S. T., Naolin, T. D., Ellingrod, V. L., & Possey, L. M. (2023). Dipiro’s pharmacotherapy: A pathophysiologic approach (12th ed.). McGraw-Hill Education.
Elantouny, N. G., Abo Bakr, A. A., EL-Sokkary, R. H., & Elshahat, Y. E. (2019). Levofloxacin versus clarithromycin-based therapy for eradication of Helicobacter pylori infection: A comparative study. Zagazig University Medical Journal, 25(4), 500–507.
Gashi, Z., Sherifi, F., & Gashi, A. (2025). Comparison of clarithromycin- and levofloxacin-based regimens as first-line triple therapy in eradication of Helicobacter pylori infection. Annals of Case Reports, 09(06), 1–5. https://doi.org/10.29011/2574-7754.102147
Goto, Y., Syam, A. F., Darnindro, N., & Hapsari, F. C. P. (2016). Prevalence and risk factors for Helicobacter pylori infection among healthy inhabitants in Northern Jakarta , Indonesia. Asian Pacific Journal of Cancer Prevention, 17(10), 4747–4753. https://doi.org/10.22034/APJCP.2016.17.10.4747
Haji-Aghamohammadi, A. A., Bastani, A., Miroliaee, A., Oveisi, S., & Safarnezhad, S. (2016). Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori infection. Caspian Journal of Internal Medicine, 7(4), 267–271.
Kamal, A., Ghazy, R. M., Sherief, D., Ismail, A., & Ellakany, W. I. (2023). Helicobacter pylori eradication rates using clarithromycin and levofloxacin ‑ based regimens in patients with previous COVID ‑ 19 treatment : a randomized clinical trial. BMC Infectious Disease, 23(36), 1–8. https://doi.org/10.1186/s12879-023-07993-8
Kao, C., Sheu, B., & Wu, J. (2016). Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomedical Journal, 39(1), 14–23. https://doi.org/10.1016/j.bj.2015.06.002
Khan, Z., Khan, A. M., Basit, A., Khan, M. A., & Ali, A. (2022). Levofloxacin versus clarithromycin for Helicobacter pylori eradication: Are 14-day regimens better than 7-day regimens. Journal of Population Therapeutics & Clinical Pharmacology, 29(3), 1620–1624. https://doi.org/10.53555/jptcp.v29i03.4462
Kumar, H. R. (2024). Updated approaches to the management of complicated peptic ulcer disease : A narrative review focus on bleeding , perforation and obstruction. Asian Journal of Medicine and Health Volume, 22(11), 172–180. https://doi.org/https://doi.org/10.9734/ajmah/2024/v22i111128.
Liu, Y., Xiao, Z., Ye, K., Xu, L., & Zhang, Y. (2023). Smoking , alcohol consumption , diabetes , body mass index , and peptic ulcer risk : A two-sample Mendelian randomization study. Frontiers in Genetics, 13:992080, 1–11. https://doi.org/10.3389/fgene.2022.992080
Malik, T. F., Gnanapandithan, K., & Singh, K. (2023). Peptic ulcer disease. StatPearls Publishing.
Mohammed, S. A., Al-lela, O. Q. B., Hussein, N. R., Hajany, R. S., & Alduhoky, L. S. (2019). Clarithromycin versus levofloxacin-based regimens for Helicobacter pylori eradication in the Kurdistan Region of Iraq: A randomized clinical trial. Gastroenterology Insights, 10, 5–9. https://doi.org/10.4081/gi.2019.8256
Moradniani, M., Mirbeik-sabzevari, Z., Jaferian, S., Shafiezadeh, S., Ardakani, M. J. E., Roozbahany, M. M., Azadbakht, S., & Sherkatolabbasieh, H. (2018). Levofloxacin based vs clarithromycin based sequential therapy in helicobacter pylori eradication ; a randomized clinical trial. Gastroenterology and Hepatology from Bed to Bench, 11(1), 20–26.
O’Rourke, J., & Bode, G. (2001). Morphology and ultrastructure. ASM Press.
Putriyanti, A., Mulyani, Y., & Isvahanie, S. R. (2024). Review: Perbandingan antara terapi antibiotik levofloxacin jangka pendek dosis tinggi dengan dosis regimen konvensional pada pasien pneumonia. Farmaka, 22(3), 452–462.
Sun, M., Liu, E., Yang, L., Cao, H., & Han, M. (2025). A scoping review of worldwide guidelines for diagnosis and treatment of Helicobacter pylori infection. BMC Systematic Reviews, 14(107), 1–15. https://doi.org/10.1186/s13643-025-02816-0
Xie, X., Ren, K., Zhou, Z., Dang, C., & Zhang, H. (2022). The global , regional and national burden of peptic ulcer disease from 1990 to 2019 : a population ‑ based study. BMC Gastroenterology, 22(58), 1–13. https://doi.org/10.1186/s12876-022-02130-2
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Nisrina Dea Almira, Tuhfatul Ulya, Raden Roro Elvina Chandra Yani, Muhammad Imam Rizqullah Ramadhan, Radinda Zyra Kaylila
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
